Better chemicals management for a Great Green World

|

article image
How and why the EU's DG International Cooperation and Development works to support better chemicals management in developing countries.

Spotlight

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are re

OTHER ARTICLES

COVID-19’S IMPACT ON CHEMICAL SUPPLY CHAINS

Article | April 8, 2020

The global COVID-19 pandemic has resulted in significant impact on chemical supply chains. Here we take a look at some of the chemicals that have been affected: Sanitization products such as Isopropyl Alcohol have experienced skyrocketing demand. Unfortunately, manufacturers are simultaneously dealing with problems that are preventing them from supplying at full capacity. While two US producers are experiencing production issues, another is having trouble with raw material Acetone supply. A fourth US producer is scheduled to restart production of IPA, but this material will take a few weeks to come online. Meeting this unprecedented demand is proving to be a challenge, and prices have increased sharply.

Read More

ACC's Jahn discusses how the chemical industry is combating COVID-19

Article | April 8, 2020

The U.S. chemical industry has a vital role to play in response to COVID-19. Following President Trump’s declaration of a national emergency, one of the first steps the American Chemistry Council took on behalf of its members was to secure federal designation of the U.S. chemical industry and its workers as “essential critical infrastructure.” This means that the Department of Homeland Security (DHS) identified the chemical industry and its employees as an industry sector critical to public health and safety, as well as economic and national security.

Read More

Sustainability: A Core Initiative for Collaboration in the Chemical Industry

Article | April 8, 2020

Legislation and pressure from stakeholders are forcing the chemical industry to find efficiencies and urgently seek out ways to reduce environmental impact, such as implementing low-carbon initiatives, maximizing energy and water efficiency and developing new innovative products and processes. Last month’s World Economic Forum added further urgency as shareholders and investment groups added new sustainability criteria to their investment considerations. As the pressure to improve sustainability rises, organizations like SusChem, the European Technology Platform for Sustainable Chemistry, are gaining visibility and traction.

Read More
CHEMICAL TECHNOLOGY

Guyana-Suriname basin: Rise from obscurity to super potential

Article | April 8, 2020

Recent discoveries in the Guyana-Suriname basin attest to estimates of 10+ Bbbl of oil resources and more than 30 Tcf of gas.1 Like many oil & gas successes, this is a story that begins with early exploration success onshore, followed by a long period of exploration disappointment in coastal to shelf regions offshore, eventually culminating in deepwater success.

Read More

Spotlight

Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK." Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic. Trabodenoson has completed Phase 2 clinical development in primary open-angle glaucoma (POAG) and ocular hypertensive (OHT) patients and is ready for Phase 3. Trabodenoson, if ultimately approved by regulatory agencies, will be a valuable, innovative product that ophthalmologists can use alone or in combination with other approved medicines for glaucoma, and would also be a new treatment option for those patients who are re

Events